4mon
Zacks.com on MSNAll You Need to Know About Actinium (ATNM) Rating Upgrade to Strong BuyActinium Pharmaceuticals (ATNM ... as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates ...
Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...
Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...
At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...
Now, Actinium is downgrading the priority of the ... which is intended for use as an induction and conditioning therapy for AML patients who need a bone marrow transplant. It consists of an ...
Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development ...
The study will look to confirm the tolerability of the combination and determine the optimal dose of Actimab-A when used with Venetoclax and ASTX-727. Dr. Avinash Desai, Actinium’s Chief Medical ...
Actinium is a clinical-stage biopharmaceutical ... external radiation conditioning regimens are toxic, restricting the use and efficacy of these potentially curative therapies.
Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results